6th August 2021


EVOBIOTECH GETS A “SEED” FUNDING OF € 1 MILLION for the development of new vaccines and therapies based on extracellular vesicles of plant origin

EvoBiotech, an innovative start-up operating in the biotechnology sector, announces the entry into the share capital of Nocturnal Labs SpA, an Operational Holding Company with a strong innovative vision, and of LuMar.

The “seed” investment for a total of € 1 million to EvoBiotech is intended for the development of a project on extracellular vesicles for oral mRNA-based vaccines, thus simplifying significantly both the distribution chain and the administration of vaccines.
The funds will also be used to consolidate EvoBiotech’s patent portfolio, also continuing in the preclinical development of a second research pipeline that applies the regenerative properties of extracellular vesicles of plant origin for the treatment of chronic wounds by exploiting their strong pro-angiogenic feature helping re-epithelialization.

“We strongly believe in EvoBiotech potential which, already at this stage, offers diversified and very promising technological development assets, based on extremely interesting scientific-technological platforms,” stated Luigi Colombo, CEO of Nocturnal Labs.

ABOUT EvoBiotech: EvoBiotech is a biotechnological startup operating within 2i3T – Company for the Management of the Business Incubator and for the Technology Transfer of the University of Turin – and was founded in 2019 by Prof. Giovanni Camussi, one of the greatest world experts on extracellular vesicles deriving from stem cells and by three scientists, Dr. Chiara Gai, Margherita Pomatto and Maria Chiara Deregibus.
EvoBiotech focuses on the development of regenerative medicine therapies based on this new type of extracellular vesicles and, in particular, aimed at advanced treatment of chronic wounds. Since 2020, the team has initiated projects involving the loading of extracellular vesicles with viral nucleic acids to be used as an oral vaccine.

ABOUT Nocturnal Labs: Nocturnal Labs is an operational holding company that supports seed-stage companies to develop products, technologies, and global businesses that advance health.
The Nocturnal labs team’s combination of research, development, clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry which can provide benefit and value for patients, doctors and healthcare systems, and reward shareholders with a sound and ethical profit. FOR FURTHER INFORMATION: